Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BOSTON SCIENTIFIC CORP Director's Dealing 2023

Feb 15, 2023

29821_dirs_2023-02-15_8d14535b-14fb-4fd0-b4ba-bea66fdd7256.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BOSTON SCIENTIFIC CORP (BSX)
CIK: 0000885725
Period of Report: 2023-02-14

Reporting Person: Butcher Arthur C (EVP& Grp Pres, MedSurg & APAC)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2023-02-14 Performance Share Units $ A 8940.0000 Acquired 2024-12-31 Common Stock (8940.0000) Direct
2023-02-14 Restricted Stock Units $ A 12690.0000 Acquired 2027-02-14 Common Stock (12690.0000) Direct
2023-02-14 Stock Option (Right to Buy) $47.2800 A 33021.0000 Acquired 2033-02-14 Common Stock (33021.0000) Direct

Footnotes

F1: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2024.

F3: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F4: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant.

F5: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant.